Evidence map›Paper›PMID 42045446›Full record

ArticleEMBO reports2026

Relevance of the antibody Fc fragment and epitope valency in protection against malaria sporozoites.

Yevel Flores-Garcia, Manuela C Aguirre-Botero, Prabhanshu Tripathi, Emily Locke, Minah Park, Shamika Mathis-Torres, Berenice Salgado-Jimenez, Sonia Herrera-Arevalo, Anisha Gladston, Beejan Asady and 3 more

Abstract read
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yevel Flores-Garcia *Bloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.
Manuela C Aguirre-Botero *Institut Pasteur, Université Paris Cité, INSERM, Malaria Infection and Immunity, BioSPC 562, ParasitInnov U1347, Paris, France.
Prabhanshu TripathiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-1282-2848
Emily LockeCenter for Vaccine Innovation and Access, PATH, Washington, DC, USA.
Minah ParkBloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.
Shamika Mathis-TorresBloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.
Berenice Salgado-JimenezBloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.ORCID 0009-0009-5143-6633
Sonia Herrera-ArevaloBloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.
Anisha GladstonInstitut Pasteur, Université Paris Cité, INSERM, Malaria Infection and Immunity, BioSPC 562, ParasitInnov U1347, Paris, France.
Beejan AsadyBloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.
Isabelle CoppensBloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA.
Rogerio Amino *Institut Pasteur, Université Paris Cité, INSERM, Malaria Infection and Immunity, BioSPC 562, ParasitInnov U1347, Paris, France. roti@pasteur.fr.ORCID 0000-0002-8086-2932
Fidel Zavala *Bloomberg School of Public Health. Department of Molecular Microbiology and Immunology. Malaria Research Institute, Baltimore, MD, USA. fzavala1@jhu.edu.ORCID 0000-0002-1414-6196

Funding

Agence Nationale de la Recherche (ANR) ANR-10-LABX-62-IBEIDAgence Nationale de la Recherche (ANR) ANR-19-CE15-0027Gates Foundation INV-001763
6 · The paper itself

Abstract

Protection against infection by Plasmodium falciparum sporozoites is mediated in part by antibodies that recognize the repeated (NPNA)3 epitopes of the circumsporozoite protein (CSP). To evaluate the role that the antibody Fc region plays in neutralizing sporozoite infectivity, we assess the protective efficacy of Fab fragments obtained from protective human monoclonal antibodies and use antibodies bearing the LALA and KA mutations known to reduce Fc functions. To determine the impact of multiple-antibody binding to CSP on protection, we use sporozoites from genetically modified P. berghei strains expressing a CSP containing different numbers of (NPNA)3 epitopes. Our results indicate that Fab fragments and Fc-mutated antibodies have a protective efficacy comparable to intact antibodies, indicating a limited role, if any, of Fc functions in sporozoites in this model system. We also determine that antibody binding to multiple adjacent epitopes and the establishment of homotypic interactions between bound antibodies may not be necessary for protection, as binding to one epitope is sufficient to strongly reduce liver burden while only two separate epitopes are needed to achieve sterile protection.

Indexed as

Antibodies, ProtozoanEpitopesImmunoglobulin Fc FragmentsMalariaSporozoitesAnimalsAntibodies, MonoclonalAntibodies, NeutralizingHumansImmunoglobulin Fab FragmentsMalaria VaccinesMicePlasmodium bergheiPlasmodium falciparumProtozoan ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, Protozoancircumsporozoite protein, ProtozoanEpitopesImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsMalaria VaccinesProtozoan Proteins

Identifiers

PMID42045446
PMCPMC13303866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.